EMBC
Embecta Corp.
Drug Manufacturers - Specialty & Generic
Market Cap$211M
5Y Perf.-89.3%
Compare Stocks
3 / 10Try these comparisons:
Stock Comparison
EMBC vs UTMD vs LFUS
Revenue, margins, valuation, and 5-year total return — side by side.
UTMD
Utah Medical Products, Inc.
Medical - Instruments & Supplies
Market Cap$206M
5Y Perf.-28.3%
LFUS
Littelfuse, Inc.
Hardware, Equipment & Parts
Market Cap$11.11B
5Y Perf.+77.1%
EMBC vs UTMD vs LFUS — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | EMBC | UTMD | LFUS |
|---|---|---|---|
| Industry | Drug Manufacturers - Specialty & Generic | Medical - Instruments & Supplies | Hardware, Equipment & Parts |
| Market Cap | $211M | $206M | $11.11B |
| Revenue (TTM) | $1.04B | $39M | $2.49B |
| Net Income (TTM) | $112M | $11M | $-40M |
| Gross Margin | 61.4% | 52.9% | 38.3% |
| Operating Margin | 27.7% | 29.6% | 2.8% |
| Forward P/E | 1.3x | 10.2x | 33.8x |
| Total Debt | $1.43B | $225K | $946M |
| Cash & Equiv. | $226M | $86M | $563M |
EMBC vs UTMD vs LFUS — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
EMBC
UTMD
LFUS
| Stock | Mar 22 | May 26 | Return |
|---|---|---|---|
| Embecta Corp. (EMBC) | 100 | 10.7 | -89.3% |
| Utah Medical Produc… (UTMD) | 100 | 71.7 | -28.3% |
| Littelfuse, Inc. (LFUS) | 100 | 177.1 | +77.1% |
Price return only. Dividends and distributions are not included.
Quick Verdict: EMBC vs UTMD vs LFUS
Each card shows where this stock fits in a portfolio — not just who wins on paper.
Bottom line: EMBC leads in 3 of 7 categories, making it the strongest pick for valuation and capital efficiency and dividend income and shareholder returns. Utah Medical Products, Inc. is the stronger pick specifically for profitability and margin quality and capital preservation and lower volatility. This set spans 2 sectors — these stocks serve different portfolio roles, not just different price points.
EMBC
Embecta Corp.
The Growth Play
EMBC has the current edge in this matchup, primarily because of its strength in growth exposure.
- Rev growth -3.8%, EPS growth 20.9%, 3Y rev CAGR -1.5%
- Lower P/E (1.3x vs 33.8x)
- 16.7% yield, 1-year raise streak, vs LFUS's 0.7%
Best for: growth exposure
UTMD
Utah Medical Products, Inc.
The Income Pick
UTMD is the clearest fit if your priority is income & stability and sleep-well-at-night.
- Dividend streak 3 yrs, beta 0.55, yield 1.9%
- Lower volatility, beta 0.55, Low D/E 0.2%, current ratio 37.62x
- Beta 0.55, yield 1.9%, current ratio 37.62x
Best for: income & stability and sleep-well-at-night
LFUS
Littelfuse, Inc.
The Long-Run Compounder
LFUS is the clearest fit if your priority is long-term compounding.
- 315.2% 10Y total return vs UTMD's 18.7%
- 8.9% revenue growth vs UTMD's -5.8%
- +133.3% vs EMBC's -65.9%
Best for: long-term compounding
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | LFUS | 8.9% revenue growth vs UTMD's -5.8% |
| Value | EMBC | Lower P/E (1.3x vs 33.8x) |
| Quality / Margins | UTMD | 29.3% margin vs LFUS's -1.6% |
| Stability / Safety | UTMD | Beta 0.55 vs LFUS's 1.76, lower leverage |
| Dividends | EMBC | 16.7% yield, 1-year raise streak, vs LFUS's 0.7% |
| Momentum (1Y) | LFUS | +133.3% vs EMBC's -65.9% |
| Efficiency (ROA) | EMBC | 10.3% ROA vs LFUS's -1.0%, ROIC 42.7% vs 1.0% |
EMBC vs UTMD vs LFUS — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
FY 2025
Segment breakdown not available.
FY 2025
EMBC vs UTMD vs LFUS — Financial Metrics
Side-by-side numbers across 3 stocks — who leads on profitability, valuation, growth, and risk.
BEST OVERALLEMBCLAGGINGLFUS
Who Leads Where
UTMD leads in 1 of 6 categories
EMBC leads 1 • LFUS leads 1 • 3 tied
Explore the data ↓LFUSLittelfuse, Inc.
1leads
UTMDUtah Medical Products…
1leads
EMBCEmbecta Corp.
1leads
6 Total Categories
CATEGORYLEADERvs UTMDvs LFUSMETRICS WON
Income & Cash FlowRevenue, margins, and cash flow strength
UTMD3/6
Valuation MetricsMultiples, price ratios, and targets
EMBC4/6
Profitability & EfficiencyROE, ROIC, leverage, and quality scores
Tied
—
Total Returns1Y, 3Y, 5Y total returns with dividends
LFUS6/6
Risk & VolatilityBeta, volatility, and downside exposure
Tied
—
Analyst OutlookRatings, price targets, and dividends
Tied
—
Income & Cash Flow (Last 12 Months)
UTMD leads this category, winning 3 of 6 comparable metrics.
Income & Cash Flow (Last 12 Months)
LFUS is the larger business by revenue, generating $2.5B annually — 64.6x UTMD's $39M. UTMD is the more profitable business, keeping 29.3% of every revenue dollar as net income compared to LFUS's -1.6%. On growth, LFUS holds the edge at +18.5% YoY revenue growth, suggesting stronger near-term business momentum.
| Metric | EMBCEmbecta Corp. | UTMDUtah Medical Prod… | LFUSLittelfuse, Inc. |
|---|---|---|---|
| RevenueTrailing 12 months | $1.0B | $39M | $2.5B |
| EBITDAEarnings before interest/tax | $316M | $14M | $227M |
| Net IncomeAfter-tax profit | $112M | $11M | -$40M |
| Free Cash FlowCash after capex | $174M | $14M | $390M |
| Gross MarginGross profit ÷ Revenue | +61.4% | +52.9% | +38.3% |
| Operating MarginEBIT ÷ Revenue | +27.7% | +29.6% | +2.8% |
| Net MarginNet income ÷ Revenue | +10.7% | +29.3% | -1.6% |
| FCF MarginFCF ÷ Revenue | +16.7% | +37.2% | +15.7% |
| Rev. Growth (YoY)Latest quarter vs prior year | -14.4% | -1.2% | +18.5% |
| EPS Growth (YoY)Latest quarter vs prior year | -2.9% | -7.0% | +69.1% |
UTMD leads this category, winning 3 of 6 comparable metrics.
Valuation Metrics
EMBC leads this category, winning 4 of 6 comparable metrics.
Valuation Metrics
At 2.2x trailing earnings, EMBC trades at a 88% valuation discount to UTMD's 18.5x P/E. On an enterprise value basis, EMBC's 3.7x EV/EBITDA is more attractive than LFUS's 83.2x.
| Metric | EMBCEmbecta Corp. | UTMDUtah Medical Prod… | LFUSLittelfuse, Inc. |
|---|---|---|---|
| Market CapShares × price | $211M | $206M | $11.1B |
| Enterprise ValueMkt cap + debt − cash | $1.4B | $121M | $11.5B |
| Trailing P/EPrice ÷ TTM EPS | 2.20x | 18.51x | -152.30x |
| Forward P/EPrice ÷ next-FY EPS est. | 1.26x | 10.25x | 33.80x |
| PEG RatioP/E ÷ EPS growth rate | — | 5.40x | — |
| EV / EBITDAEnterprise value multiple | 3.72x | 8.42x | 83.23x |
| Price / SalesMarket cap ÷ Revenue | 0.20x | 5.36x | 4.66x |
| Price / BookPrice ÷ Book value/share | — | 1.75x | 4.53x |
| Price / FCFMarket cap ÷ FCF | 1.16x | 14.41x | 30.35x |
EMBC leads this category, winning 4 of 6 comparable metrics.
Profitability & Efficiency
Evenly matched — EMBC and UTMD each lead in 5 of 9 comparable metrics.
Profitability & Efficiency
UTMD delivers a 9.6% return on equity — every $100 of shareholder capital generates $10 in annual profit, vs $-2 for LFUS. UTMD carries lower financial leverage with a 0.00x debt-to-equity ratio, signaling a more conservative balance sheet compared to LFUS's 0.39x. On the Piotroski fundamental quality scale (0–9), EMBC scores 6/9 vs LFUS's 5/9, reflecting solid financial health.
| Metric | EMBCEmbecta Corp. | UTMDUtah Medical Prod… | LFUSLittelfuse, Inc. |
|---|---|---|---|
| ROE (TTM)Return on equity | — | +9.6% | -1.6% |
| ROA (TTM)Return on assets | +10.3% | +9.3% | -1.0% |
| ROICReturn on invested capital | +42.7% | +25.0% | +1.0% |
| ROCEReturn on capital employed | +37.8% | +9.6% | +1.1% |
| Piotroski ScoreFundamental quality 0–9 | 6 | 6 | 5 |
| Debt / EquityFinancial leverage | — | 0.00x | 0.39x |
| Net DebtTotal debt minus cash | $1.2B | -$86M | $383M |
| Cash & Equiv.Liquid assets | $226M | $86M | $563M |
| Total DebtShort + long-term debt | $1.4B | $225,000 | $946M |
| Interest CoverageEBIT ÷ Interest expense | 39.48x | — | -0.93x |
Evenly matched — EMBC and UTMD each lead in 5 of 9 comparable metrics.
Total Returns (Dividends Reinvested)
LFUS leads this category, winning 6 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in LFUS five years ago would be worth $17,565 today (with dividends reinvested), compared to $1,236 for EMBC. Over the past 12 months, LFUS leads with a +133.3% total return vs EMBC's -65.9%. The 3-year compound annual growth rate (CAGR) favors LFUS at 20.1% vs EMBC's -43.3% — a key indicator of consistent wealth creation.
| Metric | EMBCEmbecta Corp. | UTMDUtah Medical Prod… | LFUSLittelfuse, Inc. |
|---|---|---|---|
| YTD ReturnYear-to-date | -68.2% | +14.5% | +68.5% |
| 1-Year ReturnPast 12 months | -65.9% | +22.6% | +133.3% |
| 3-Year ReturnCumulative with dividends | -81.7% | -27.3% | +73.4% |
| 5-Year ReturnCumulative with dividends | -87.6% | -17.8% | +75.7% |
| 10-Year ReturnCumulative with dividends | -87.6% | +18.7% | +315.2% |
| CAGR (3Y)Annualised 3-year return | -43.3% | -10.1% | +20.1% |
LFUS leads this category, winning 6 of 6 comparable metrics.
Risk & Volatility
Evenly matched — UTMD and LFUS each lead in 1 of 2 comparable metrics.
Risk & Volatility
UTMD is the less volatile stock with a 0.55 beta — it tends to amplify market swings less than LFUS's 1.76 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. LFUS currently trades 93.0% from its 52-week high vs EMBC's 22.9% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | EMBCEmbecta Corp. | UTMDUtah Medical Prod… | LFUSLittelfuse, Inc. |
|---|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 1.31x | 0.55x | 1.76x |
| 52-Week HighHighest price in past year | $15.55 | $71.81 | $475.00 |
| 52-Week LowLowest price in past year | $3.55 | $52.00 | $188.08 |
| % of 52W HighCurrent price vs 52-week peak | +22.9% | +89.7% | +93.0% |
| RSI (14)Momentum oscillator 0–100 | 14.4 | 43.8 | 71.1 |
| Avg Volume (50D)Average daily shares traded | 1.2M | 13K | 266K |
Evenly matched — UTMD and LFUS each lead in 1 of 2 comparable metrics.
Analyst Outlook
Evenly matched — EMBC and LFUS each lead in 1 of 2 comparable metrics.
Analyst Outlook
Analyst consensus: EMBC as "Sell", LFUS as "Buy". Consensus price targets imply 237.1% upside for EMBC (target: $12) vs -9.4% for LFUS (target: $400). For income investors, EMBC offers the higher dividend yield at 16.69% vs LFUS's 0.65%.
| Metric | EMBCEmbecta Corp. | UTMDUtah Medical Prod… | LFUSLittelfuse, Inc. |
|---|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Sell | — | Buy |
| Price TargetConsensus 12-month target | $12.00 | — | $400.00 |
| # AnalystsCovering analysts | 4 | — | 11 |
| Dividend YieldAnnual dividend ÷ price | +16.7% | +1.9% | +0.7% |
| Dividend StreakConsecutive years of raises | 1 | 3 | 16 |
| Dividend / ShareAnnual DPS | $0.59 | $1.23 | $2.89 |
| Buyback YieldShare repurchases ÷ mkt cap | +2.7% | +4.0% | +0.2% |
Evenly matched — EMBC and LFUS each lead in 1 of 2 comparable metrics.
Key Takeaway
UTMD leads in 1 of 6 categories (Income & Cash Flow). EMBC leads in 1 (Valuation Metrics). 3 tied.
Best OverallEmbecta Corp. (EMBC)Leads 1 of 6 categories
Loading custom metrics...
EMBC vs UTMD vs LFUS: Key Questions Answered
10 questions · data-driven answers · updated daily
01Is EMBC or UTMD or LFUS a better buy right now?
For growth investors, Littelfuse, Inc.
(LFUS) is the stronger pick with 8. 9% revenue growth year-over-year, versus -5. 8% for Utah Medical Products, Inc. (UTMD). Embecta Corp. (EMBC) offers the better valuation at 2. 2x trailing P/E (1. 3x forward), making it the more compelling value choice. Analysts rate Littelfuse, Inc. (LFUS) a "Buy" — based on 11 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which has the better valuation — EMBC or UTMD or LFUS?
On trailing P/E, Embecta Corp.
(EMBC) is the cheapest at 2. 2x versus Utah Medical Products, Inc. at 18. 5x. On forward P/E, Embecta Corp. is actually cheaper at 1. 3x.
03Which is the better long-term investment — EMBC or UTMD or LFUS?
Over the past 5 years, Littelfuse, Inc.
(LFUS) delivered a total return of +75. 7%, compared to -87. 6% for Embecta Corp. (EMBC). Over 10 years, the gap is even starker: LFUS returned +315. 2% versus EMBC's -87. 6%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
04Which is safer — EMBC or UTMD or LFUS?
By beta (market sensitivity over 5 years), Utah Medical Products, Inc.
(UTMD) is the lower-risk stock at 0. 55β versus Littelfuse, Inc. 's 1. 76β — meaning LFUS is approximately 218% more volatile than UTMD relative to the S&P 500. On balance sheet safety, Utah Medical Products, Inc. (UTMD) carries a lower debt/equity ratio of 0% versus 39% for Littelfuse, Inc. — giving it more financial flexibility in a downturn.
05Which is growing faster — EMBC or UTMD or LFUS?
By revenue growth (latest reported year), Littelfuse, Inc.
(LFUS) is pulling ahead at 8. 9% versus -5. 8% for Utah Medical Products, Inc. (UTMD). On earnings-per-share growth, the picture is similar: Embecta Corp. grew EPS 20. 9% year-over-year, compared to -172. 5% for Littelfuse, Inc.. Over a 3-year CAGR, EMBC leads at -1. 5% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
06Which has better profit margins — EMBC or UTMD or LFUS?
Utah Medical Products, Inc.
(UTMD) is the more profitable company, earning 29. 3% net margin versus -3. 0% for Littelfuse, Inc. — meaning it keeps 29. 3% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: EMBC leads at 30. 5% versus 1. 6% for LFUS. At the gross margin level — before operating expenses — EMBC leads at 62. 9%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
07Is EMBC or UTMD or LFUS more undervalued right now?
On forward earnings alone, Embecta Corp.
(EMBC) trades at 1. 3x forward P/E versus 33. 8x for Littelfuse, Inc. — 32. 5x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for EMBC: 237. 1% to $12. 00.
08Which pays a better dividend — EMBC or UTMD or LFUS?
All stocks in this comparison pay dividends.
Embecta Corp. (EMBC) offers the highest yield at 16. 7%, versus 0. 7% for Littelfuse, Inc. (LFUS).
09Is EMBC or UTMD or LFUS better for a retirement portfolio?
For long-horizon retirement investors, Utah Medical Products, Inc.
(UTMD) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 55), 1. 9% yield). Littelfuse, Inc. (LFUS) carries a higher beta of 1. 76 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (UTMD: +18. 7%, LFUS: +315. 2%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
10What are the main differences between EMBC and UTMD and LFUS?
These companies operate in different sectors (EMBC (Healthcare) and UTMD (Healthcare) and LFUS (Technology)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.
In terms of investment character: EMBC is a small-cap deep-value stock; UTMD is a small-cap quality compounder stock; LFUS is a mid-cap quality compounder stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform all of them.
Revenue Growth>
%
(EMBC: -14.4% · UTMD: -1.2%)Net Margin>
%
(EMBC: 10.7% · UTMD: 29.3%)P/E Ratio<
x
(EMBC: 2.2x · UTMD: 18.5x)You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.